Specializing in supporting biological science, these state-of-the-art facilities significantly enhance capabilities for internal project initiatives and material supply.

Biosynth, a leading developer and supplier of critical raw materials and services for diagnostics, vaccines, and pharmaceutical industries, is pleased to announce the opening of their Biosynth Biological Technology site at Lifebay, an innovative technology park in Suzhou, China. This new site houses state-of-the-art facilities including a Bio-laboratory which significantly enhances capabilities for internal project development initiatives and material supply into the domestic Life Science market.

The official opening ceremony on 29^th October was attended by local and national dignitaries, Life Science and Pharma customers, and partners of Biosynth, as well as representatives of Biosynth’s Leadership Team along with Board Representative Nico Haller, Director at KKR.

Dr. Thomas Eisele, Chief Operations Officer, announced, “We are thrilled to be formally opening Biosynth Biological Technology. This facility represents our dedication to innovation and excellence and adds a crucial production site for internal materials as well as acting as a distribution and handling hub for our customers in the region.”

Philip Noone, Chief Commercial Officer, commented, “Through our new Lifebay facility in Suzhou, Biosynth will serve IVD companies across China directly, with our comprehensive Biologics, Chemicals, and Complex Peptides offering. Our new site will allow us for the first time in our history to offer our unique diagnostic solutions for infectious diseases, oncology, and autoimmunity targeting emerging pathogens.”

Alessandra Vismara, General Manager for China, added, “This has been a significant project to build and equip this facility. As part of the next phase, we will be commissioning our biosafety level 2 laboratories, which means that we can handle and supply even more biological diagnostic tools. Enzyme development and production for local customers will complete the portfolio of these facilities.”

About Biosynth

Biosynth supplies critical materials, securing life science supply chains with global research, manufacturing, and distribution facilities. Supplying the pharmaceutical, vaccine, and diagnostic sectors; where Chemistry meets Biology, Products meet Services and Innovation meets Quality, Biosynth is at the Edge of Innovation. With end-to-end manufacturing services, Biosynth’s expertise and capability spans Complex Chemicals, Peptides, and Key Biologics, all from one trusted partner. Headquartered in Staad, Switzerland, Biosynth is owned amongst others by KKR, Ampersand Capital Partners, and management. Learn more at www.biosynth.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241030170821/en/

Biosynth
Alannah Wheeler
+44 7984 525560 marketing@biosynth.com

Tags

More Like This

Biosynth to Offer Complex Chemistry Solutions at Greater Scales Following Acquisition of VIO Chemicals

Tsingke Showcases Cutting-Edge Biologics Solutions at Biologics 2024

Tsingke Successfully Showcases Innovations at BIO-Europe 2024

AsymBio Establishes Integrated Technology Platforms Spanning the Full Biopharmaceutical Development Lifecycle

Syngenta Builds World-Leading Research Center for Agricultural Bioscience – Powered by Advanced Technology and AI

Tsingke Biotech and iGeneTech Forge Strategic Partnership to Lead Synthetic Biology Advancements

Tsingke Biotech Showcased AI-Powered Biomanufacturing Solutions at 2025 Festival of Biologics

XBiotech to Begin Constructing New R&D Facility on its 48-acre Campus